首页 | 本学科首页   官方微博 | 高级检索  
     


Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
Authors:G. Curigliano  V. Mueller  V. Borges  E. Hamilton  S. Hurvitz  S. Loi  R. Murthy  A. Okines  E. Paplomata  D. Cameron  L.A. Carey  K. Gelmon  G.N. Hortobagyi  I. Krop  S. Loibl  M. Pegram  D. Slamon  J. Ramos  E. Winer
Affiliation:1. Istituto Europeo di Oncologia, Milan, IRCCS and University of Milano, Milan, Italy;2. Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany;3. University of Colorado Hospital, Aurora, USA;4. Sarah Cannon Research Institute/Tennessee Oncology – Nashville, Nashville, USA;5. University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, USA;6. Peter MacCallum Cancer Centre, Melbourne, Australia;7. MD Anderson Cancer Center, Houston, USA;8. The Royal Marsden NHS Foundation Trust, London, UK;9. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, USA;10. Edinburgh Cancer Research Centre, Edinburgh, UK;11. UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA;12. British Columbia Cancer – Vancouver Centre, Vancouver, Canada;13. Dana-Farber Cancer Institute, Boston, USA;14. German Breast Group, Neu-Isenburg, Germany;15. Stanford Cancer Institute, Palo Alto, USA;16. Seagen Inc., Bothell, USA
Abstract:
Keywords:metastatic breast cancer  human epidermal growth factor receptor 2-positive (HER2)  brain metastases  tucatinib  trastuzumab  capecitabine
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号